NLRP3 and metabolic dysfunction-associated steatotic liver disease: The NLRP3 inflammasome inhibitor, MCC950, was so effective in preventing the deleterious effects of NAFLD plasma that no differences could be observed between NAFLD plasma and healthy subjects' plasma, as regarding mitochondrial membrane potential, triglycerides content and mitoROS release.